Camlin Fine Sciences Ltd

- No new plant CAPEX planned; only annual maintenance CAPEX of Rs. 40-50 crores. - No new long-term borrowing planned; current debt is being repaid at Rs. 40-50 crores per year. - Peak debt levels referred to are current peak; no additional long-term debt is on the cards. - Management is monitoring working capital needs and revenue growth that may influence debt requirements, but currently, no new debt approval. - No mention of any new equity fundraising plans during the discussed period. - Focus remains on organic growth and managing existing assets/liabilities without fresh capital infusion.

- Currently, no new plants are planned. - Maintenance CAPEX is ongoing, approximately Rs. 40-50 crores annually due to existing large plants. - No new CAPEX plans have been approved or are currently on the cards. - The company focuses on maintenance and sustaining current operations rather than expansion CAPEX in the near term. - As revenue increases, there might be future requirements, but nothing specific is planned now.

- Revenue guidance for FY'27 is approximately Rs. 2,200 crores; for FY'28, around Rs. 2,400 crores. - Vanillin volume guidance for FY'27 is 4,000 metric tons, indicating a growth of about 50%-60% from FY'26. - Blend business projected to grow by 20%-25% over FY'26, targeting around Rs. 1,350 crores in FY'27 from Rs. 1,000 crores. - Vitafor (animal feed segment) expected to grow 40%-50% in FY'27 from current top-line of €12-13 million to €17-18 million. - Ethyl Vanillin production to commence shortly, targeting approximately 300 tons by March next quarter, adding to volumes. - Overall, a combined growth in Vanillin and Blend segments expected to drive revenue and margin improvement.

- Revenue guidance for FY'27 is approximately Rs. 2,200 crores, growing to Rs. 2,400 crores in FY'28. - Vanillin sales are expected to grow significantly with a volume target of about 4,000 metric tons in FY'27. - Blend business is projected to grow around 25% over FY'26, contributing to overall revenue growth. - Gross margins are expected to improve by 1%-2% to reach approximately 46%-47% in FY'27, aided by higher Vanillin realizations and Blend growth. - EBITDA margins are anticipated to increase to a range of 12%-14% driven by volume growth and improved realizations. - Cost pressures from Straights business with margin compression are being offset by gains in Vanillin and Blends. - Operational improvements expected from cessation of cash bleed in European and China operations post-liquidation. - No major CAPEX planned; focus remains on controlled growth with maintenance CAPEX of Rs. 40-50 crores annually.

- The transcripts provided do not explicitly mention the current or expected order book or pending orders for Camlin Fine Sciences Limited. - However, the company indicates strong demand growth, especially in blends and Vanillin segments. - They expect Vanillin sales to increase to about 4,000 tons in FY'27, up from 2,300-2,400 tons, reflecting optimism about order flow. - Blends segment is projected to grow 25% over FY'26. - The company is actively working on expanding market access, including launching new products like ethyl Vanillin and expanding in markets like the US, Europe, Brazil, and India. - The recent acquisition of Vinpai is expected to contribute to increasing sales and margins as volume builds. - There is also reference to managing channel inventory in Vanillin to optimize pricing and sales timing. - Maintenance CAPEX is around Rs. 40-50 crores, with no new plants or major CAPEX planned, implying demand absorption will rely on existing capacities.